Vantage logo

Bluebird split looks premature

Today’s safety scare with Lentiglobin calls into question the logic behind Bluebird’s planned business separation.

Vantage logo

Finding the next Prevail

An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.